Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03604315
PHASE1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Sponsor: M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.

Official title: Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2018-12-18

Completion Date

2027-06-30

Last Updated

2025-10-14

Healthy Volunteers

No

Interventions

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

PROCEDURE

Computed Tomography

Undergo \[18F\]FTT PET/CT

RADIATION

Fludeoxyglucose F-18

Given IV

RADIATION

Fluorine F 18 Fluorthanatrace

Given IV

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

PROCEDURE

Positron Emission Tomography

Undergo \[18F\]FTT PET/CT

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States